(Date:10/7/2008)... WASHINGTON, Oct. 7 /PRNewswire-USNewswire/ -- ...ecent winner of Dancing With the Stars, has been,n...ation Christmas Seals,Campaign in an effort to hel...sion: to prevent lung disease and promote lung hea...ls tradition began in 1907,to conquer Tuberculosis...
(Date:10/7/2008)...Less likely to feel distress, more likely to enjoy... TUESDAY, Oct. 7 (HealthDay News) -- End-of-life d...atient do not result in more distress for patients...interventions and enhanced quality of life in a pa... "For the past two decades, the debate has been ar...
(Date:10/7/2008)..., Surprise announcement of planned bequest comes .../PRNewswire-USNewswire/ -- Just over one year,ago,...million gift to the,University of Michigan, to end..., treating and preventing human disease., Today, ...n --,announcing that he will bequeath an additiona...
(Date:10/7/2008)...These brain-damaged individuals show signs of awar...AY, Oct. 7 (HealthDay News) -- Severely brain-dam... still feel pain and require painkilling treatment...ally conscious state (MCS) is different than a per...efulness without awareness of self or surroundings...
Breaking Medicine News(10 mins):Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Patients Benefit From End-of-Life Discussions With a Doctor 2Health News:Patients Benefit From End-of-Life Discussions With a Doctor 3Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:Patients in Minimally Conscious State May Still Feel Pain 2(Date:10/7/2008)... FORT COLLINS, Colo., Oct. 7 /- A...examining embryonic stem cell self-renewal,report...lastim (recombinant,human serum albumin) was an ef...cell culture., The article entitled, "The ground ...sed that researchers used Cellastim as a recombina...
(Date:10/7/2008)... CAMBRIDGE, Mass., Oct. 7 /- Tali... data on several of the Company,s pipeline,candida...ement Workshop in,Basel, Switzerland. The data hig...l models of complement-mediated diseases., "These...vitro studies,presented at the conference, reveal ...
(Date:10/7/2008)... Several abstracts highlighting CIMZIA,s long-...n,s disease patients presented at American College.../- Data from two studies,pr...f Gastroenterology,(ACG) Annual Meeting demonstrat...EGylated anti-TNF alpha (Tumor Necrosis Factor alp...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- A...today that a poster entitled "RDEA119, a Potent,an...in Dextran Sulfate,Sodium (DSS) -- induced Chronic...ollege of Gastroenterology (ACG) 2008 Annual Meeti... data from a preclinical study of,RDEA119, the Com...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4The story of Max Perutz a pioneering biologist with a remarkable passion for life 2832 1Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27 16388 1Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27 16388 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 1Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 1ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 7...Shock Protein 90 Inhibitor,Reveal Further Evidence..., CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, ... Inc. (Nasdaq:INFI) and,MedImmune, Inc. (Nasdaq:ME... Phase I clinical trial of the companies, heat sho...nts with relapsed,refractory gastrointestinal str...
...Newswire-FirstCall/ --,Alexza Pharmaceuticals, Inc... Annual NCDEU Meeting the results of a Phase I cli...s being developed for,the treatment of acute agita...DEU meeting is co-sponsored by the National Instit...linical,Psychopharmacology. , The poster presentat...
Other Medicine Technology:Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine),Clinical Data at the Annual NCDEU Meeting 2...ontinuous low-flow nebulizer performance. Patented...allows for optimal medication and Heliox delivery ...vere asthma, COPD and pneumonia in both routine an... mouth and T-piece to deliver high-output, low-flo...
... diverse medical products for more than 58 years. ...anding reputation for innovation, quality and cust...ecognized brands include the Labtron® line of ... products, Bristoline® microscopes, HealthTeam...
...contains everything the health care professional n...ickly and efficiently: 7 nebulizers, T-piece and m...yringe and needle., ,Shipped 5 kits per case., ,...ed Use: AsthmaKit is a procedural kit providing th...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
Medicine Products: